Skip to content
Screener

Annexon ANNX Debt-to-equity

Debt-to-equity at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
0.0×
Jade Biosciences logo
Jade BiosciencesJBIO
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
0.0×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
0.0×
Vor Biopharma logo
Vor BiopharmaVOR
0.5×+0.2×

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$886.39M+244%
Enterprise value$736.61M+381%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Current ratio6.4×-1.6×

Where this comes from

Calculated from Annexon’s reported figures.

Based on the most recent quarter.

The source filing: Annexon’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 4:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211931

FAQ

What is Annexon's debt-to-equity?
Annexon (ANNX) reported debt-to-equity of 0.1× in Q1 2026.
How has Annexon's debt-to-equity changed year-over-year?
Annexon's debt-to-equity increased by 7.1% year-over-year, from 0.1× to 0.1×.
What is the long-term trend for Annexon's debt-to-equity?
Over 4 years (2021 to 2025), Annexon's debt-to-equity has grown at a -4.5% compound annual growth rate (CAGR), from 0.1× to 0.1×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Annexon's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude